Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$17MCash on Hand
14.4mo Cash Runway
Follow ALLR by emailGet an email when ALLR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ALLR, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Financing Streeterville exchanged a $3,000,000 partitioned portion of a note for 3,000 shares of Series B Preferred Stock with a $1,050 stated value and 9% preferred return. No cash was received. The company also announced expanded eligibility in its Phase 2 stenoparib ovarian cancer trial. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 2, 2026 ·
Deal Allarity agreed to settle a $4.9 million liability owed to Novartis plus interest for a $1.0 million payment, with mutual releases upon receipt. It also announced its first revenue-generating CLIA laboratory services contract with a European biotech. Form 8-K · SEC filing · Press release
Oct 30, 2026 ·
Financing Allarity terminated its $6.0 million common stock purchase agreement with Tumim Stone Capital, effective October 28, 2026. The company said it will pursue alternative financing and that no early termination penalty is payable. Form 8-K · SEC filing
Oct 30, 2026 ·
Financing Allarity terminated its common stock purchase agreement with Tumim Stone Capital effective October 28, 2026, ending the primary offering of up to $6,000,000 of shares. Resale coverage for shares previously sold to Tumim remains in place. Form 424B5 · SEC filing
Oct 1, 2026 ·
Allarity says recently awarded patents and its CLIA-certified in-house lab extend the commercial viability of stenoparib and its DRP companion diagnostic. At AACR 2026, higher DRP scores were linked to longer overall survival in an exploratory analysis of a prior ovarian cancer cohort. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Allarity expanded its in-house medical laboratory to add proteomics and cell line research, supporting mechanism-of-action work on stenoparib and external research services. The company said the expansion will not affect its current cash runway. Form 8-K · SEC filing · Press release
Sep 16, 2026 ·
Japan Patent Office granted a key patent (No. 7917283) covering the stenoparib-specific DRP companion diagnostic, with protection in Japan into 2039. The company says it strengthens stenoparib's developability in Japan. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Recruiting · Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer Registry primary completion date, not a results date
Jun 2027 · N/A · Recruiting · Clinical Pre-screening Protocol for Ovarian Cancer Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not ALLR's own candidates): Ixabepilone.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ALLR holds $17M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.5M/quarter from operations,
an estimated runway of 14.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:48 · Elevated
Cash runway 14 months +18
ATM program on file since Sep 2024 +15
Shelf registration (S-3, Dec 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these financial statements.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Share count 15,997,108 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ALLR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALLR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.